QUECTEL-WIRELESS
21.6.2022 14:02:48 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced its dual-band multi-constellation GNSS module LC29H . Built using the Airoha AG3335 platform, the LC29H is available in multiple variants and optionally integrates RTK and DR. The LC29H series offers high performance, power-efficient solutions to meet market needs of high-precision positioning at the centimeter and decimeter levels. These modules are perfectly suited to an expanding market for autonomous lawn mowers, drones, precision agriculture, micro-mobility scooters and delivery robots as well as other industrial and autonomous applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005631/en/
“High precision positioning with centimeter level accuracy is becoming increasingly vital for many new IoT applications. Robotics, UAV and industrial applications needing precise navigation are driving new market requirements and we are very excited to launch our newest generation of high-precision positioning modules,” said Patrick Qian, CEO of Quectel. “With our focus of providing best-in-class, easy-to-use and affordable solutions to our customers, we believe the IoT market is ready for mass adoption of cm-level positioning modules for a wide range of scenarios.”
The LC29H concurrently receives and processes signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS maximizes satellite signal availability. The module supports L1 and L5 dual-band signal reception, thereby ensuring that terminals can speed up convergence time, improve positioning accuracy, and achieve fast response times even when the signal is interrupted. The dual band design significantly mitigates the multipath effect experienced near high-rise buildings or in deep urban canyons, and provides reliable positioning performance.
In addition, some versions contain 6-axis IMU inertial sensors (3-axis accelerometer + 3-axis gyroscope), and integrate RTK and DR positioning algorithms, allowing for continuous lane-level accurate positioning in scenarios where the satellite signal is partially or completely blocked, such as underground parking lots, tunnels, urban-canyons or forests. When the satellite signal is re-acquired, the LC29H combines inertial sensor data with GNSS signals, and the integrated navigation can provide fast convergence times and decimeter level positioning accuracies.
In order to improve the performance when used with a passive Antenna, the LC29H has a built-in LNA and an internal SAW filter, ensuring high sensitivity and excellent positioning accuracy.
The LC29H adopts a 12nm process, dual-frequency receiver chip and advanced low-power management, thereby enabling low-power GNSS sensing and position fixing. This makes the module an ideal solution for power-sensitive and battery-powered devices including handheld devices, asset trackers, and shared vehicles.
Featuring an LCC form factor and an industry standard footprint size of 12.2 mm × 16.0 mm × 2.5 mm, the LC29H series design allows for easy system integration and smooth migration of legacy designs to the latest high precision GNSS technologies.
The LC29H is available in four product variants each targeting different application scenarios. The LC29H(EA) offers a perfect solution for a growing market of agricultural drones as well as electricity power detection terminals, and is able to improve the anti-interference capability of complex systems. The LC29H(BA) is well suited to agricultural machinery and specialized vehicles, and the LC29H(DA) can enable centimeter-level accuracy in connected lawnmowers and safety helmets at competitive cost.
Additionally, the LC29H can be bundled with Quectel’s wide range of off-the-shelf and customized GNSS antennas . Both passive and active antennas are provided to satisfy customer requirements for high precision positioning. Customized connector types and cable lengths are available as along with comprehensive antenna design support including simulation and testing services. The manufacturing of customized antenna solutions is also available to fast track customer product development.
The LC29H will be showcased at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com
, LinkedIn
, Facebook
, and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005631/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom